GSK is acquiring US biotech company IDRx for $1.15bn, enhancing its oncology portfolio with IDRX-42, a promising TKI for treating gastrointestinal cancers. This deal reflects GSK's strategic focus on addressing unmet medical needs in oncology.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing